Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases. … SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc

  2. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    It is an experimental therapy that is being developed by NeoRx Corporation. … SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in

  3. Drug

    N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide

    go.drugbank.com/drugs/DB03456
    Experimental

    These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. It is known to target cathepsin K. … N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide is a solid. This compound belongs to the n-acyl-alpha amino acids and derivatives.

  4. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. … The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.

  5. Drug

    p-Fluorofentanyl

    go.drugbank.com/drugs/DB09177
    ExperimentalIllicit

    p-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before … they appeared. p-Fluorofentanyl is made with the same synthetic route as fentanyl, but by substituting para-fluoroaniline for aniline in the synthesis.

  6. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  7. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  8. Drug

    Mephentermine

    go.drugbank.com/drugs/DB01365
    ApprovedWithdrawn

    A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.

  9. Drug

    Digitoxin

    go.drugbank.com/drugs/DB01396
    ApprovedWithdrawn

    A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749